Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 1.00 |
| ▸ | CES2 | O00748 | 2/20 | 0.68 |
| ▸ | CES1 | P23141 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151881 | 1.00 | PARP1 (1.00) | PARP1CES2CES1HDAC1HDAC6 | |
| SCHEMBL18867942 | 1.00 | PARP1 (1.00) | PARP1CES2CES1HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL28788495 | 0.98 | PARP1 (0.96) | PARP1CES2CES1HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL30460793 | 0.98 | PARP1 (0.96) | PARP1CES2CES1HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL4381068 | 0.98 | PARP1 (0.96) | PARP1CES2CES1HDAC1HDAC6 | |
| Formic Acid SCHEMBL31754222 | 0.92 | PARP1 (0.85) | PARP1CES2CES1HDAC1HDAC6 | |
| Phosphoric Acid SCHEMBL27813451 | 0.92 | PARP1 (0.85) | PARP1CES2CES1HDAC1HDAC6 | |
| 3-Aminobenzamide SCHEMBL27579659 | 0.90 | PARP1 (0.81) | PARP1CES2CES1HDAC1HDAC6 | |
| Benzoic Acid SCHEMBL28349303 | 0.90 | PARP1 (0.81) | PARP1CES2CES1HDAC1HDAC6 | |
| SCHEMBL27675361 | 0.89 | PARP1 (0.79) | PARP1CES2CES1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-4651717-A1 | COMPOUNDS FOR INCREASING FROST TOLERANCE IN PLANTS | VIB VZW (BE) | 2025-11-26 | — | — | EP | claimed |
| US-12410174-B1 | Small molecular inhibitors of sting signaling compositions and methods of use | TYERELL IMMUNOTHERAPEUTICS INC (US) | 2025-09-09 | — | — | US | claimed |
| CN-120049017-A | Org/ZnSO4Electrolyte, preparation method thereof and application of electrolyte in secondary battery | 同济大学 | 2025-05-27 | — | — | CN | claimed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-115298170-B | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118696036-A | PARP1 inhibitors | 突触活化疗法股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118507836-B | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| WO-1999032477-A1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-01 | — | — | WO | claimed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | claimed |
| US-5874444-A | CONTROLLING CELL AGING | GERON CORPORATION (US) | 1999-02-23 | — | — | US | claimed |
| EP-0696270-B1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 1998-11-04 | — | — | EP | claimed |
| US-5811454-A | 3-FLUOROBENZAMIDES WITH NITROGEN MUSTARD GROUPS; ANTICARCINOGENIC AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-09-22 | — | — | US | claimed |
| WO-1998027975-A1 | POLY(ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT DISEASES ASSOCIATED WITH CELLULAR SENESCENCE | GERON CORPORATION (US) | 1998-07-02 | — | — | WO | claimed |
| JP-H08509490-A | — | — | 1996-10-08 | — | — | JP | claimed |
| EP-0696270-A1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-02-14 | — | — | EP | claimed |
| WO-1994025429-A1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-11-10 | — | — | WO | claimed |
| WO-1993014062-A1 | ANTHELMINTIC β-KETOAMIDES | THE UPJOHN COMPANY (US) | 1993-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410174-B1 | Small molecular inhibitors of sting signaling compositions and methods of use | STING1, IRF3, MAVS | PARP1 246/4885CES2 4707/4885CES1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.